Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;12(10):11248-11253.
doi: 10.1002/cam4.5832. Epub 2023 Apr 20.

Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience

Idoroenyi Amanam  1 , Janny Yao  2 , Alfredo Puing  3 , Ni-Chun Tsai  4 , Diana Samuels  2 , Dat Ngo  2 , Stephanie Ho  2 , Haris Ali  1 , Ahmed Aribi  1 , Shukaib Arslan  1 , Andrew Artz  1 , Myo Htut  1 , Paul Koller  1 , Amandeep Salhotra  1 , Karamjeet Sandhu  1 , Liana Nikolaenko  1 , Anna Pawlowska  5 , Geoffrey Shouse  1 , Anthony Stein  1 , Guido Marcucci  1 , Stephen Forman  1 , Ryotaro Nakamura  1 , Sanjeet Dadwal  3 , Monzr M Al Malki  1
Affiliations

Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience

Idoroenyi Amanam et al. Cancer Med. 2023 May.

Abstract

Introduction: In November 2020, the FDA issued an emergency use authorization (EUA) for monoclonal antibody (mAb) therapy in patients with mild-to-moderate COVID-19 at high risk for disease progression.

Methods: We retrospectively reviewed 38 adult hematology patients who received mAbs from 11/2020 to 2/2021.

Results: Thirty (79%) patients received bamlanivimab and 8 (21%) casirivimab-imdevimab. Four (11%) patients were hospitalized due to COVID-19, two (5%) progressed to severe disease and one patient (3%) died within 30 days from COVID-19 disease. Most patients (n = 34, 89%) ultimately tested negative for SARS-CoV-2, with 34% (n = 13) clearing the virus within 14 days after mAb infusion. The median time to clearance of viral shedding was 25.5 days (range: 7-138). After mAb infusion, most patients with hematological malignancies (HM) (n = 10/15; 67%) resumed therapy for underlying disease with a median delay of 21.5 days (range: 12-42). We observed a significant difference in hospitalization among patients who received a HCT versus non-HCT (0% n = 0/26 and 36% n = 4/11, respectively; p < 0.01).

Conclusions: This study demonstrates that SARS-CoV-2 specific mAb was safe and may reduce hospitalization compared to what is reported in malignant hematology patients at high risk for disease progression. Our HCT cohort patients had less hospitalization rate compared with HM cohort patients.

Keywords: cancer stem cells; hematologic malignancies; leukemia; target therapy; viral infection.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant conflicts of interest to declare.

References

    1. COVID‐19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Accessed January 10, 2022. https://coronavirus.jhu.edu/map.html
    1. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID‐19: a randomized clinical trial. JAMA. 2021;325(7):632‐644. - PMC - PubMed
    1. Hoffmann M, Kleine‐Weber H, Schroeder S, et al. SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271‐80.e8. - PMC - PubMed
    1. U.S. Food & Drug Administration Treatment COVID‐19 EUA FDA Letter ; 2022. Accessed January 10, 2022. https://www.regeneron.com/downloads/treatment‐covid19‐eua‐fda‐letter.pdf
    1. Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab ; 2020. Accessed January 10, 2022. https://www.fda.gov/media/143603/download